IN2012DN01913A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01913A IN2012DN01913A IN1913DEN2012A IN2012DN01913A IN 2012DN01913 A IN2012DN01913 A IN 2012DN01913A IN 1913DEN2012 A IN1913DEN2012 A IN 1913DEN2012A IN 2012DN01913 A IN2012DN01913 A IN 2012DN01913A
- Authority
- IN
- India
- Prior art keywords
- derivatives
- stearoyl
- modulate
- activity
- coa desaturase
- Prior art date
Links
- 108010087894 Fatty acid desaturases Proteins 0.000 abstract 2
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24763409P | 2009-10-01 | 2009-10-01 | |
| PCT/EP2010/064672 WO2011039358A1 (en) | 2009-10-01 | 2010-10-01 | Pyrazole derivatives which modulate stearoyl-coa desaturase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01913A true IN2012DN01913A (de) | 2015-07-24 |
Family
ID=43066810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1913DEN2012 IN2012DN01913A (de) | 2009-10-01 | 2010-10-01 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130011361A1 (de) |
| EP (1) | EP2483264A1 (de) |
| JP (1) | JP2013506638A (de) |
| KR (1) | KR20120080226A (de) |
| CN (1) | CN102574841A (de) |
| AU (1) | AU2010302577A1 (de) |
| BR (1) | BR112012007509A2 (de) |
| CA (1) | CA2776294A1 (de) |
| CL (1) | CL2012000797A1 (de) |
| CO (1) | CO6761294A2 (de) |
| CR (1) | CR20120134A (de) |
| EA (1) | EA201200545A1 (de) |
| EC (1) | ECSP12011837A (de) |
| IL (1) | IL218294A0 (de) |
| IN (1) | IN2012DN01913A (de) |
| MA (1) | MA33693B1 (de) |
| MX (1) | MX2012003938A (de) |
| PE (1) | PE20121439A1 (de) |
| PH (1) | PH12012500648A1 (de) |
| SG (1) | SG178869A1 (de) |
| TN (1) | TN2012000085A1 (de) |
| WO (1) | WO2011039358A1 (de) |
| ZA (1) | ZA201201390B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック， インコーポレイテッド | 癌を治療するためのｓｃｄ１アンタゴニスト |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
| EP3700934A4 (de) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | Verbindungen und verwendungen davon |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| EP3914593A4 (de) | 2019-01-24 | 2022-11-02 | Yumanity Therapeutics, Inc. | Verbindungen und verwendungen davon |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE272650T1 (de) | 1999-03-29 | 2004-08-15 | Uutech Ltd | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| ATE397625T1 (de) | 1999-09-28 | 2008-06-15 | Bayer Corp | Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung |
| PT1315831E (pt) | 2000-02-24 | 2010-11-04 | Xenon Pharmaceuticals Inc | Estearoil-coa dessaturase para identificar agentes terapêuticos que reduzem triglicéridos |
| WO2002026944A2 (en) | 2000-09-26 | 2002-04-04 | Xenon Genetics, Inc. | METHODS AND COMPOSITIONS EMPLOYING A NOVEL STEAROYL-CoA DESATURASE-hSCD5 |
| JP4958786B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| EP2289510A1 (de) * | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterozyklische Derivate zur Behandlung von durch Stearoyl-Coa-Desaturase-Enzyme verursachten Krankheiten |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| EP2054408B1 (de) * | 2006-08-15 | 2016-07-13 | Novartis AG | Zur Behandlung von mit erhöhtem Lipidspiegel verbundenen Krankheiten geeignete heterocyclische Verbindungen |
| WO2008024390A2 (en) * | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
| US8236835B2 (en) * | 2006-09-22 | 2012-08-07 | Novartis Ag | Heterocyclic inhibitors of stearoyl-CoA desaturase |
| US8068738B2 (en) * | 2007-02-21 | 2011-11-29 | Tte Technology, Inc. | System and method for decoding infra-red (IR) signals |
| UA105000C2 (uk) * | 2008-02-20 | 2014-04-10 | Новартіс Аг | ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ |
-
2010
- 2010-10-01 IN IN1913DEN2012 patent/IN2012DN01913A/en unknown
- 2010-10-01 SG SG2012013066A patent/SG178869A1/en unknown
- 2010-10-01 EP EP10761003A patent/EP2483264A1/de not_active Withdrawn
- 2010-10-01 WO PCT/EP2010/064672 patent/WO2011039358A1/en not_active Ceased
- 2010-10-01 AU AU2010302577A patent/AU2010302577A1/en not_active Abandoned
- 2010-10-01 PE PE2012000427A patent/PE20121439A1/es not_active Application Discontinuation
- 2010-10-01 PH PH1/2012/500648A patent/PH12012500648A1/en unknown
- 2010-10-01 US US13/391,900 patent/US20130011361A1/en not_active Abandoned
- 2010-10-01 BR BR112012007509A patent/BR112012007509A2/pt not_active IP Right Cessation
- 2010-10-01 MX MX2012003938A patent/MX2012003938A/es not_active Application Discontinuation
- 2010-10-01 KR KR1020127011127A patent/KR20120080226A/ko not_active Ceased
- 2010-10-01 JP JP2012531447A patent/JP2013506638A/ja active Pending
- 2010-10-01 CN CN201080044452XA patent/CN102574841A/zh active Pending
- 2010-10-01 EA EA201200545A patent/EA201200545A1/ru unknown
- 2010-10-01 CA CA2776294A patent/CA2776294A1/en not_active Abandoned
-
2012
- 2012-02-21 TN TNP2012000085A patent/TN2012000085A1/en unknown
- 2012-02-23 IL IL218294A patent/IL218294A0/en unknown
- 2012-02-24 ZA ZA2012/01390A patent/ZA201201390B/en unknown
- 2012-03-20 CR CR20120134A patent/CR20120134A/es unknown
- 2012-03-30 CL CL2012000797A patent/CL2012000797A1/es unknown
- 2012-04-03 CO CO12056222A patent/CO6761294A2/es not_active Application Discontinuation
- 2012-04-26 MA MA34807A patent/MA33693B1/fr unknown
- 2012-04-27 EC ECSP12011837 patent/ECSP12011837A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2012000797A1 (es) | 2013-08-09 |
| CN102574841A (zh) | 2012-07-11 |
| CR20120134A (es) | 2012-05-17 |
| CA2776294A1 (en) | 2011-04-07 |
| PE20121439A1 (es) | 2012-11-06 |
| MX2012003938A (es) | 2012-08-03 |
| CO6761294A2 (es) | 2013-09-30 |
| BR112012007509A2 (pt) | 2016-11-22 |
| KR20120080226A (ko) | 2012-07-16 |
| ECSP12011837A (es) | 2012-06-29 |
| US20130011361A1 (en) | 2013-01-10 |
| AU2010302577A1 (en) | 2012-03-15 |
| EP2483264A1 (de) | 2012-08-08 |
| MA33693B1 (fr) | 2012-10-01 |
| TN2012000085A1 (en) | 2013-09-19 |
| EA201200545A1 (ru) | 2012-12-28 |
| PH12012500648A1 (en) | 2012-11-12 |
| SG178869A1 (en) | 2012-04-27 |
| IL218294A0 (en) | 2012-04-30 |
| WO2011039358A1 (en) | 2011-04-07 |
| ZA201201390B (en) | 2012-10-31 |
| JP2013506638A (ja) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3014B1 (ar) | مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة | |
| WO2009156484A3 (en) | Organic compounds | |
| MY153263A (en) | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | |
| MX2009006728A (es) | Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd. | |
| MX2009003080A (es) | Compuestos organicos heterociclicos. | |
| WO2007143597A3 (en) | Organic compounds | |
| IN2012DN01913A (de) | ||
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| MY181898A (en) | Heterocyclic compounds and uses thereof | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| NZ603151A (en) | N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives | |
| MX2011013577A (es) | Composiciones y metodos para tratar esclerosis lateral amiotrofica. | |
| PH12012501680A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP2129672A4 (de) | Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür | |
| IN2012DN03404A (de) | ||
| PH12012501963A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| MX2011013324A (es) | Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor. | |
| MX2013005699A (es) | Composiciones de interferon-beta estables conservadas. | |
| TN2010000598A1 (en) | Organic compounds | |
| TN2010000378A1 (en) | Heterocyclic inhibitors of stearoyl-coa desaturase | |
| TN2010000354A1 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
| UA47407U (uk) | Похідні нітрилопіридину |